MoCRA Compliance Checklist for US Brands Manufacturing in Korea

Quick Answer

MoCRA requires US brands manufacturing in Korea to register facilities with the FDA, list products, maintain safety records, and report adverse events. Key steps include facility registration, product listing, GMP adherence, labeling compliance, and safety substantiation record-keeping.

Why MoCRA Is the First Thing You Should Google

I get it. You found a Korean manufacturer, you picked your formulas, and you're ready to launch. The last thing you want to hear is that there's a wall of FDA paperwork between you and your first shipment.

But here's the thing: MoCRA (the Modernization of Cosmetics Regulation Act of 2022) isn't some distant regulatory threat. As of August 2026, the FDA has over 14,000 registered cosmetic facilities and nearly a million listed products on file. They launched a public adverse event dashboard in September 2025 that lets anyone, your customers, your competitors, plaintiff lawyers, see safety complaints in real time. And Customs and Border Protection is actively flagging shipments from unregistered facilities.

The brands that treated MoCRA as optional in 2024 learned the hard way. Amazon pulled thousands of cosmetic listings for non-compliance. Shipments sat in customs for weeks. Some founders lost entire production runs to border holds.

The good news? If you're manufacturing in Korea, most of the compliance work is straightforward. You just need to know who's responsible for what, and when to do each step. That's what this checklist is for.

Your Job vs. Your Manufacturer's Job

This is where most founders get confused, so let me make it simple.

Your Korean manufacturer is responsible for: registering their facility with the FDA (through a portal called Cosmetics Direct), designating a US agent (required for all foreign facilities), and renewing that registration every two years. They should also be able to provide stability testing data, microbial testing results, and challenge testing documentation for every formula they produce for you.

You, the US brand owner, are responsible for everything else. Under MoCRA, the "responsible person" is whoever's name appears on the product label. For indie brands, that's you. Product listing with the FDA, adverse event reporting, safety substantiation records, labeling compliance, marketing claims: all yours.

Your manufacturer handles their facility. You handle your brand. The line is that clean.

The Checklist: Eight Steps Before Your First Shipment

I've walked dozens of founders through this process. Here's the order that works.

Step 1: Verify your manufacturer's FDA registration. Ask for their FEI number (Facility Establishment Identifier). Every registered facility has one. If they can't produce it, that's a problem. An unregistered facility means your shipment gets flagged the moment it hits a US port. Don't assume they're registered because they're large or well-known. Verify.

Step 2: Confirm your manufacturer has a designated US agent. MoCRA requires every foreign facility to have a US-based agent on file with the FDA. This person serves as a point of contact for FDA communications. Your manufacturer should handle this, but confirm it's in place before you commit to production.

Step 3: Get your safety documentation in order. Request complete INCI ingredient lists, stability test reports, microbial test results, and challenge test data for every product. You need to maintain records that demonstrate "adequate substantiation of safety," meaning evidence reviewed by qualified experts that supports a reasonable certainty your product is safe. The FDA won't test your product before you sell it, but they can ask for your records at any time. Korean ODMs with experience exporting to the US typically have this documentation ready. If yours doesn't, that's a red flag.

Step 4: Review your labels against FDA requirements. A label that's perfectly legal in Korea can get your shipment detained in the US. Your US label needs: a product identity statement, net quantity on the front panel, your name and US address as the distributor, a complete ingredient list in descending order using INCI nomenclature, and any required warnings. Everything in English. If you keep Korean text for aesthetic reasons, all required information must still appear in English. Get your final artwork reviewed before you go to print. Reprinting packaging after a border rejection is one of the most expensive mistakes I see.

Step 5: Audit every word of your marketing copy. Cosmetic claims describe appearance: "visibly reduces the look of fine lines," "leaves skin looking more radiant." Those are fine. Drug claims describe function: "reduces wrinkles," "stimulates collagen production," "treats acne." The FDA considers those drug claims, which means your product would need FDA drug approval before it can be sold. K-beauty marketing tends to lean heavy on efficacy language. Review your labels, your website copy, your Amazon listing, your social posts. Amazon's compliance systems scan for drug-claim language and will deactivate your listing without warning.

Not sure whether your labels and claims pass muster? Book a free 15-minute call with me and I'll walk you through what to fix before you go to print.

Step 6: List every product with the FDA. Product listing is separate from facility registration, and it's your responsibility as the responsible person. File through Cosmetics Direct (it's free) and include your full ingredient list for each SKU. New products must be listed within 120 days of entering the US market. Update your listings annually, or within 60 days if anything changes. There's a small business exemption if your average US cosmetic sales are under $1 million over a rolling three-year period, but it doesn't apply to eye-area products, injectables, or products that alter appearance for more than 24 hours. My advice: list anyway. It's free, it protects you, and you'll need it the moment your sales grow.

Step 7: Set up your adverse event reporting process. If a customer experiences a serious adverse event (hospitalization, significant disfigurement, a reaction requiring medical intervention), you must report it to the FDA within 15 business days. You also need to submit any new material information within one year of the initial report, again within 15 business days. Keep records of all adverse events, serious or not, for six years (three years if you qualify as a small business). Set this up before your first sale: a dedicated email address for customer complaints, a log to track reports, and someone on your team who knows what "serious" means under MoCRA.

Step 8: Brief your customs broker. When your shipment arrives at a US port, CBP files documentation that triggers FDA review through a system called PREDICT. Things that reliably get shipments detained: unregistered manufacturing facilities, drug-claim language on labels, unapproved color additives, products from manufacturers on FDA import alerts, and documentation mismatches between your filing and what's actually in the box. Work with a broker who specializes in cosmetics imports. They know which Affirmation of Compliance codes to include and how to respond if your shipment gets flagged. A detained shipment can cost you weeks and thousands of dollars. For the full import-side breakdown, see our FDA rules for importing Korean skincare.

What Changed in 2026

MoCRA has been rolling out in phases since 2022. Here's what's new or newly enforced as of mid-2026.

The FAERS cosmetic dashboard is live. As of September 2025, the FDA publishes real-time adverse event data for cosmetic products. Anyone can search it: consumers, retailers, competitors, lawyers. If complaints are piling up against a specific product or ingredient, the data is public. Monitor it for your own products and your category.

Registration renewals are being enforced. The biennial renewal requirement that many brands ignored in 2024 is now actively enforced. The Cosmetics Direct portal added registration status and renewal date fields in February 2026 to make tracking easier. If your manufacturer's registration lapsed, your next shipment is at risk.

FDA can now order mandatory recalls. Before MoCRA, cosmetic recalls were voluntary. FDA issued draft guidance in December 2025 on how it will use its new mandatory recall authority for products that present serious health risks. If your product gets flagged, "voluntary" isn't the only option anymore.

GMP regulations are coming. FDA hasn't finalized Good Manufacturing Practice rules for cosmetics yet, but draft regulations are expected. The standard will likely align with ISO 22716, which most established Korean ODMs already follow. If your manufacturer doesn't have documented quality systems, start that conversation now.

Fragrance allergen labeling is on the horizon. FDA missed its December 2025 deadline for fragrance allergen disclosure rules, but a proposed rule is expected in late 2026. When it arrives, approximately 60 fragrance allergens will need to be individually listed on labels. If your products contain fragrance, start planning for reformulation or relabeling now.

The Three Mistakes That Cost Founders the Most

After helping dozens of brands navigate this process, I see the same three mistakes over and over.

Assuming the manufacturer handles everything. Your Korean ODM handles their facility registration. They do not handle your product listings, your adverse event reporting, your labeling compliance, or your marketing claims. I've had founders discover this gap when their shipment was already sitting in a US warehouse with non-compliant labels. Fix the division of responsibility before production starts.

Treating label review as an afterthought. Label errors are the single most common reason Korean cosmetic shipments get detained at US customs. Net quantity placement, ingredient order, missing English translations, drug-claim language buried in marketing copy. A professional label review costs a few hundred dollars. A border rejection costs thousands, plus the weeks you lose while your inventory sits in a bonded warehouse.

Ignoring the claims problem. K-beauty brands love efficacy language. "Repairs skin barrier." "Boosts collagen." "Anti-aging treatment." Every one of those is a drug claim under US law. The FDA doesn't care that it's standard marketing language in Korea. Amazon doesn't care either. They'll pull your listing without warning and make you resubmit with compliant copy. Audit your claims before you launch, not after your first takedown notice.

What Altameet Handles for You

I started Altameet because I watched too many founders burn time and money on compliance problems that were completely avoidable. Here's what we do: we vet Korean manufacturers for active FDA registration before we connect you. We coordinate safety documentation handoffs so you have your substantiation files organized before production. We flag labeling issues before you go to print. And we walk you through the product listing process so you're not guessing at Cosmetics Direct.

We don't replace your regulatory counsel or your customs broker. But we make sure the manufacturing side of your compliance is locked down before your first shipment leaves Korea.

For the per-unit cost breakdown of manufacturing in Korea, see our skincare manufacturing cost guide. If you're still deciding between ODM, OEM, and private label models, start with our OEM vs ODM vs private label primer.

I'm Liz, and I run Altameet from New York. If you're at the compliance stage and want to make sure nothing falls through the cracks before your products leave Korea, the fastest way to get clarity is a quick call. I'll tell you exactly what you need to have in place. Book your free 15-min call with Liz